Study of the Efficacy and Safety of NST-1024 Versus Placebo in Subjects With Hypertriglyceridemia
NCT ID: NCT05889156
Last Updated: 2025-04-24
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE2
Total Enrollment
50 participants
Study Classification
INTERVENTIONAL
Study Start Date
2023-06-30
Study Completion Date
2025-04-11
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is a Phase IIa,multicentre proof of concept study consisting of 2 study periods to study Treatment with NST-1024 as an adjunct to diet to reduce triglyceride (TG) levels in subjects with TG levels of ≥500 mg/dL and ≤2000 mg/dL; determined by percentage change in TG from baseline after 28 days of treatment.
The two periods consist of:
1. A 3-week screening period that includes a TG qualifying period, and
2. A 28-days, double-blind, randomized, parallel group, placebo-controlled treatment period.
Subjects will return to the study site for a follow-up visit 2 weeks after the last dose.
Approximately 50 subjects will be randomized at approximately 15-35 centers in USA.
The two periods consist of:
1. A 3-week screening period that includes a TG qualifying period, and
2. A 28-days, double-blind, randomized, parallel group, placebo-controlled treatment period.
Subjects will return to the study site for a follow-up visit 2 weeks after the last dose.
Approximately 50 subjects will be randomized at approximately 15-35 centers in USA.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia
NCT05852431
Severe Hypertriglyceridemia
ACTIVE_NOT_RECRUITING
PHASE3
Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Mild or Moderate Renal Impairment
NCT03011450
Severe Hypertriglyceridemia
COMPLETED
PHASE3
Safety, Pharmacokinetics and Pharmacodynamics of LGT209 in Healthy Volunteers With Elevated Cholesterol and in Hypercholesterolemic Patients Treated With Statins
NCT01859455
Hypercholesterolemia
LDL Cholesterol
COMPLETED
PHASE1
Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)
NCT01047501
Hypertriglyceridemia
COMPLETED
PHASE3
Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function
NCT03001817
Severe Hypertriglyceridemia
COMPLETED
PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
High Triglycerides
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
TRIPLE
Participants
Caregivers
Investigators
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Matched Placebo
Group Type
PLACEBO_COMPARATOR
Placebo
Intervention Type
OTHER
matched placebo to active arm
NST-1024
NST-1024 400 mg BID
Group Type
ACTIVE_COMPARATOR
NST-1024
Intervention Type
DRUG
400 mg BID
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NST-1024
400 mg BID
Intervention Type
DRUG
Placebo
matched placebo to active arm
Intervention Type
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Understanding of the study procedures, willing to adhere to the study schedules, and agreement to participate in the study by giving written informed consent prior to screening (Visit 1 Week -3\]) assessments;
2. Men or women 18 to 79 years of age, inclusive;
3. If on statin or non-statin lipid-altering therapy, such as ezetimibe, niacin \>200 mg/day, bempedoic acid, fibrates, prescription omega-3 products, other consumer products containing omega-3 fatty acids, or other herbal products or dietary supplements with potential lipid and glucose-altering effects, subject's use must be stable for ≥28 days prior to the first TG baseline qualifying measurement (i.e., Visit 1 \[Week -3\]), and should remain stable thereafter for the duration of study participation;
4. Fasting TG levels ≥500 mg/dL and ≤2000 mg/dL (based on an average \[arithmetic mean\] of Visit 1 and Visit 2). Note: In cases in which a subject's average TG level from Visit 1 and Visit 2 falls outside the range for entry into the study, an additional visit (Visit 2a) can be arranged up to 7 days after Visit 2 for an additional measurement of fasting TG levels. If a third sample is collected, entry into the double-blind treatment period will be based on the average of the highest TG value from Visit 1 and 2 and the Visit 2a value. Neither one of the two values used for the arithmetic mean can be less than 400 mg/dL;
5. If using oral or injectable weight loss drug, subjects must maintain stable dose of all oral and injectable weight loss drugs (e.g., GLP-1 receptor agonists) for at least 3 months prior to screening (i.e., Visit 1 \[Week -3\]), and during participation in the study.
6. Willingness to maintain stable diet and physical activity level throughout the study
7. If a smoker, no plans to change smoking habits during the study period.
8. Agree to use appropriate contraceptive methods based on biological sex and child-bearing potential as outlined in Section 12.5 of the protocol.
9. Agree to abstain from sperm or egg donation through 90 or 30 days, respectively, after administration of the last dose of IP.
2. Men or women 18 to 79 years of age, inclusive;
3. If on statin or non-statin lipid-altering therapy, such as ezetimibe, niacin \>200 mg/day, bempedoic acid, fibrates, prescription omega-3 products, other consumer products containing omega-3 fatty acids, or other herbal products or dietary supplements with potential lipid and glucose-altering effects, subject's use must be stable for ≥28 days prior to the first TG baseline qualifying measurement (i.e., Visit 1 \[Week -3\]), and should remain stable thereafter for the duration of study participation;
4. Fasting TG levels ≥500 mg/dL and ≤2000 mg/dL (based on an average \[arithmetic mean\] of Visit 1 and Visit 2). Note: In cases in which a subject's average TG level from Visit 1 and Visit 2 falls outside the range for entry into the study, an additional visit (Visit 2a) can be arranged up to 7 days after Visit 2 for an additional measurement of fasting TG levels. If a third sample is collected, entry into the double-blind treatment period will be based on the average of the highest TG value from Visit 1 and 2 and the Visit 2a value. Neither one of the two values used for the arithmetic mean can be less than 400 mg/dL;
5. If using oral or injectable weight loss drug, subjects must maintain stable dose of all oral and injectable weight loss drugs (e.g., GLP-1 receptor agonists) for at least 3 months prior to screening (i.e., Visit 1 \[Week -3\]), and during participation in the study.
6. Willingness to maintain stable diet and physical activity level throughout the study
7. If a smoker, no plans to change smoking habits during the study period.
8. Agree to use appropriate contraceptive methods based on biological sex and child-bearing potential as outlined in Section 12.5 of the protocol.
9. Agree to abstain from sperm or egg donation through 90 or 30 days, respectively, after administration of the last dose of IP.
Exclusion Criteria
1. Body mass index \>50 kg/m2;
2. Participation in another clinical study involving an investigational agent within 30 days prior to screening or 5½ half-lives whichever is longer (Visit 1 \[Week -3\]);
3. Type 1 diabetes mellitus;
4. HbA1c \> 9.5% at screening (Visit 1 \[Week -3\]);
5. History of stroke, myocardial infarction, life-threatening arrhythmia, or coronary revascularization within 6 months prior to screening;
6. History of chronic pancreatitis or acute pancreatitis in the last year. Subjects at risk of developing pancreatitis (e.g., known cholelithiasis, known alcohol abuse or multiple incidences of acute pancreatitis) per the PI's assessment are excluded. Subjects with a history of acute pancreatitis due to gallstones who have been treated with cholecystectomy are allowed.
7. History of symptomatic gallstone disease unless treated with cholecystectomy;
8. History of nephrotic range (\>3 g/day) proteinuria;
9. Estimated glomerular filtration rate (eGFR) \< 45 mL/min/1.73 m2
10. QTcF interval of \>450ms for males or \>470ms for females
11. A history of additional risk factors for torsades de pointes (TdP) (e.g., heart failure, hypokalaemia, family history of Long QT Syndrome)
12. The use of concomitant medications that prolong the QT/QTc interval (Table 1);
13. History or evidence of major and clinically significant hepatic, pulmonary, renal, hematologic, gastrointestinal (including clinically significant malabsorption), endocrine, immunologic, dermatologic, neurologic, psychiatric, oncologic, or allergic (including drug allergies, but excluding untreated or treated seasonal allergies at the time of dosing) disease that would interfere with the conduct of the study or interpretation of the data;
14. Known lipoprotein lipase impairment or deficiency (Fredrickson Type I), apolipoprotein C-II deficiency, or familial dysbetalipoproteinemia (Fredrickson Type III);
15. Requirement for peritoneal dialysis or haemodialysis for renal insufficiency;
16. History of malignancy, unless:
I. All treatment for the malignancy was completed ≥2 years prior to screening and there is no evidence of disease; II. Curatively resected squamous or basal cell carcinomas of the skin, carcinomas in situ of the cervix or uterus, ductal breast cancer in situ or low-grade prostate cancer III. Squamous cell or basal cell skin carcinomas that are not requiring tumour directed treatment during the subject's participation in the study
17. History of bariatric surgery less than 2 years prior to randomization. A history of bariatric surgery utilizing the gastric bypass technique (Roux-en-Y) or biliopancreatic diversion with duodenal switch is exclusionary;
18. Uncontrolled hypertension;
19. Known to be infected with human immunodeficiency virus (HIV) AND who are not on stable antiretroviral therapy OR have a confirmed plasma HIV-1 RNA (Viral Load) \> lower limit of detection despite antiretroviral therapy OR have a CD4+ T-cell count \<350 cell/μL OR a history of acquired immunodeficiency syndrome(AIDS);
20. Hepatitis B or C:
I. Acute or chronic Hepatitis B infection based on a positive hepatitis B surface antigen (HBsAg) test at screening (Visit 1 \[Week -3\]). Subjects with a past hepatitis B virus (HBV) infection or resolved HBV infection (defined by presence of hepatitis B core antibody (HBcAb) and absence of HbsAg are eligible if confirmed with negative HBV DNA test performed at screening; II. Positive test for hepatitis C antibody at screening (Visit 1 \[Week -3\]), except for those who have been successfully treated for hepatitis C infection and have achieved sustained virologic response for ≥1 year and who have a negative reflex HCV RNA test;
21. Anticipation of major surgery during the screening or double-blind treatment periods of the study;
22. Treatment with chronic prescription pharmacotherapy for metabolic or CV disease management or risk factor modification (e.g., antihypertensive and antidiabetic medications) that has not been stable for ≥28 days prior to screening (Visit 1 \[Week -3\]);
23. Ongoing treatment with cyclophosphamide (unless chronic oral administration for inflammatory conditions such as rheumatoid arthritis or inflammatory bowel disease), or isotretinoin;
24. Treatment with tamoxifen, estrogens, or progestins that has not been stable for ≥28 days prior to screening (Visit 1 \[Week -3\]);
25. Use of systemic corticosteroids at a dose \>7.5mg daily prednisolone equivalent (per Appendix A) ≤28 days prior to screening or anticipated use during study. Use of local injectable, inhaled, nasal administration, topical corticosteroids, or low dose glucocorticoids (≤7.5 mg prednisolone equivalent) is permitted. Low dose oral glucocorticoids should have been used for ≥ 3 months and stable for ≥ 28 days prior to baseline (Visit 3);
26. Thyroid-stimulating hormone (TSH) \> 2.0 x upper limit of normal (ULN), clinical evidence of hypothyroidism, or thyroid hormone therapy that has not been stable for ≥6 weeks prior to screening (Visit 1 \[Week -3\]);
27. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>2.5 x ULN, unless exercise-related;
28. Unexplained CK concentration \>5 × ULN or CK elevation due to known muscle disease (e.g., polymyositis, mitochondrial dysfunction);
29. Other recent or current serious disease that may interfere with the conduct of the study (renal, ophthalmic, pulmonary, hepatic, biliary, gastrointestinal, mental disorder, infectious disease, or cancer);
30. Blood donation of ≥1 pint (0.5 L) within 8 weeks prior to screening (Visit 1 \[Week -3\]) or anticipated blood donation during study, or plasma donation within 7 days prior to screening (Visit 1 \[Week -3\]);
31. History of illicit drug use or alcohol abuse within 1 year of screening (Visit 1 \[Week -3\]). Alcohol abuse is defined as \>21 standard drinks per week in men and \>14 standard drinks per week in women, on average;
32. Any condition or therapy, which, in the opinion of the investigator, might pose a risk to the subject or make participation in the study not in the subject's best interest;
33. Poor mental function or any other reason to expect subject difficulty in complying with the requirements of the study; or in the investigator's opinion, not able to comply with study procedures.
34. Pregnancy or breastfeeding.
2. Participation in another clinical study involving an investigational agent within 30 days prior to screening or 5½ half-lives whichever is longer (Visit 1 \[Week -3\]);
3. Type 1 diabetes mellitus;
4. HbA1c \> 9.5% at screening (Visit 1 \[Week -3\]);
5. History of stroke, myocardial infarction, life-threatening arrhythmia, or coronary revascularization within 6 months prior to screening;
6. History of chronic pancreatitis or acute pancreatitis in the last year. Subjects at risk of developing pancreatitis (e.g., known cholelithiasis, known alcohol abuse or multiple incidences of acute pancreatitis) per the PI's assessment are excluded. Subjects with a history of acute pancreatitis due to gallstones who have been treated with cholecystectomy are allowed.
7. History of symptomatic gallstone disease unless treated with cholecystectomy;
8. History of nephrotic range (\>3 g/day) proteinuria;
9. Estimated glomerular filtration rate (eGFR) \< 45 mL/min/1.73 m2
10. QTcF interval of \>450ms for males or \>470ms for females
11. A history of additional risk factors for torsades de pointes (TdP) (e.g., heart failure, hypokalaemia, family history of Long QT Syndrome)
12. The use of concomitant medications that prolong the QT/QTc interval (Table 1);
13. History or evidence of major and clinically significant hepatic, pulmonary, renal, hematologic, gastrointestinal (including clinically significant malabsorption), endocrine, immunologic, dermatologic, neurologic, psychiatric, oncologic, or allergic (including drug allergies, but excluding untreated or treated seasonal allergies at the time of dosing) disease that would interfere with the conduct of the study or interpretation of the data;
14. Known lipoprotein lipase impairment or deficiency (Fredrickson Type I), apolipoprotein C-II deficiency, or familial dysbetalipoproteinemia (Fredrickson Type III);
15. Requirement for peritoneal dialysis or haemodialysis for renal insufficiency;
16. History of malignancy, unless:
I. All treatment for the malignancy was completed ≥2 years prior to screening and there is no evidence of disease; II. Curatively resected squamous or basal cell carcinomas of the skin, carcinomas in situ of the cervix or uterus, ductal breast cancer in situ or low-grade prostate cancer III. Squamous cell or basal cell skin carcinomas that are not requiring tumour directed treatment during the subject's participation in the study
17. History of bariatric surgery less than 2 years prior to randomization. A history of bariatric surgery utilizing the gastric bypass technique (Roux-en-Y) or biliopancreatic diversion with duodenal switch is exclusionary;
18. Uncontrolled hypertension;
19. Known to be infected with human immunodeficiency virus (HIV) AND who are not on stable antiretroviral therapy OR have a confirmed plasma HIV-1 RNA (Viral Load) \> lower limit of detection despite antiretroviral therapy OR have a CD4+ T-cell count \<350 cell/μL OR a history of acquired immunodeficiency syndrome(AIDS);
20. Hepatitis B or C:
I. Acute or chronic Hepatitis B infection based on a positive hepatitis B surface antigen (HBsAg) test at screening (Visit 1 \[Week -3\]). Subjects with a past hepatitis B virus (HBV) infection or resolved HBV infection (defined by presence of hepatitis B core antibody (HBcAb) and absence of HbsAg are eligible if confirmed with negative HBV DNA test performed at screening; II. Positive test for hepatitis C antibody at screening (Visit 1 \[Week -3\]), except for those who have been successfully treated for hepatitis C infection and have achieved sustained virologic response for ≥1 year and who have a negative reflex HCV RNA test;
21. Anticipation of major surgery during the screening or double-blind treatment periods of the study;
22. Treatment with chronic prescription pharmacotherapy for metabolic or CV disease management or risk factor modification (e.g., antihypertensive and antidiabetic medications) that has not been stable for ≥28 days prior to screening (Visit 1 \[Week -3\]);
23. Ongoing treatment with cyclophosphamide (unless chronic oral administration for inflammatory conditions such as rheumatoid arthritis or inflammatory bowel disease), or isotretinoin;
24. Treatment with tamoxifen, estrogens, or progestins that has not been stable for ≥28 days prior to screening (Visit 1 \[Week -3\]);
25. Use of systemic corticosteroids at a dose \>7.5mg daily prednisolone equivalent (per Appendix A) ≤28 days prior to screening or anticipated use during study. Use of local injectable, inhaled, nasal administration, topical corticosteroids, or low dose glucocorticoids (≤7.5 mg prednisolone equivalent) is permitted. Low dose oral glucocorticoids should have been used for ≥ 3 months and stable for ≥ 28 days prior to baseline (Visit 3);
26. Thyroid-stimulating hormone (TSH) \> 2.0 x upper limit of normal (ULN), clinical evidence of hypothyroidism, or thyroid hormone therapy that has not been stable for ≥6 weeks prior to screening (Visit 1 \[Week -3\]);
27. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>2.5 x ULN, unless exercise-related;
28. Unexplained CK concentration \>5 × ULN or CK elevation due to known muscle disease (e.g., polymyositis, mitochondrial dysfunction);
29. Other recent or current serious disease that may interfere with the conduct of the study (renal, ophthalmic, pulmonary, hepatic, biliary, gastrointestinal, mental disorder, infectious disease, or cancer);
30. Blood donation of ≥1 pint (0.5 L) within 8 weeks prior to screening (Visit 1 \[Week -3\]) or anticipated blood donation during study, or plasma donation within 7 days prior to screening (Visit 1 \[Week -3\]);
31. History of illicit drug use or alcohol abuse within 1 year of screening (Visit 1 \[Week -3\]). Alcohol abuse is defined as \>21 standard drinks per week in men and \>14 standard drinks per week in women, on average;
32. Any condition or therapy, which, in the opinion of the investigator, might pose a risk to the subject or make participation in the study not in the subject's best interest;
33. Poor mental function or any other reason to expect subject difficulty in complying with the requirements of the study; or in the investigator's opinion, not able to comply with study procedures.
34. Pregnancy or breastfeeding.
Minimum Eligible Age
18 Years
Maximum Eligible Age
79 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
NorthSea Therapeutics B.V.
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama - Heersink School of Medicine
Birmingham, Alabama, United States
Site Status
Alliance for Multispecialty Research, LLC (AMR) - Daphne
Daphne, Alabama, United States
Site Status
Alliance for Multispecialty Research, LLC (AMR) - Phoenix
Tempe, Arizona, United States
Site Status
Velocity Clinical Research, San Diego
La Mesa, California, United States
Site Status
Velocity Clinical Research, North Hollywood
North Hollywood, California, United States
Site Status
Velocity Clinical Research - Costal Heart
Santa Ana, California, United States
Site Status
Lynn Institute of Denver
Aurora, Colorado, United States
Site Status
Velocity Clinical Research, New Smyrna Beach
Edgewater, Florida, United States
Site Status
Clearwater Cardiovascular Consultants
Largo, Florida, United States
Site Status
Floridian Clinical Research
Miami Lakes, Florida, United States
Site Status
Metabolic Research Institute, Inc.
West Palm Beach, Florida, United States
Site Status
Lifeline Primary Care/ CCT Research
Lilburn, Georgia, United States
Site Status
Velocity Clinical Research - Boise
Meridian, Idaho, United States
Site Status
Deaconess Clinic - Indiana
Evansville, Indiana, United States
Site Status
Velocity Clinical Research, Valparaiso
Valparaiso, Indiana, United States
Site Status
Alliance for Multispecialty Research, LLC (AMR) - Newton
Newton, Kansas, United States
Site Status
University of Louisville - UoL Physicians Outpatient Center
Louisville, Kentucky, United States
Site Status
Troy Internal Medicine
Troy, Michigan, United States
Site Status
Clay Platte Family Medicine / CCT Research
Kansas City, Missouri, United States
Site Status
Velocity Clinical Research - Kearney
Lincoln, Nebraska, United States
Site Status
Cenexel HRI
Berlin, New Jersey, United States
Site Status
Velocity Clinical Research - Cincinnati
Cincinnati, Ohio, United States
Site Status
Velocity Clinical Research - Cleveland
Cleveland, Ohio, United States
Site Status
Hatboro Medical Associates/ CCT Research
Hatboro, Pennsylvania, United States
Site Status
Mercado Medical Practice / CCT Research
Philadelphia, Pennsylvania, United States
Site Status
Palmetto Clinical Reserach
Summerville, South Carolina, United States
Site Status
Velocity Clinical Research - Union
Union, South Carolina, United States
Site Status
Apex Mobile Clinical Research
Bellaire, Texas, United States
Site Status
Pinnacle Clinical Research - San Antonio
San Antonio, Texas, United States
Site Status
Ogden Clinic, Mount View/CCT Research
Pleasant View, Utah, United States
Site Status
Velocity Clinical Research - Salt Lake City
Salt Lake City, Utah, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NST-1024-03
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Efficacy Study to Treat Subjects With Severe Hypertriglyceridemia
NCT01229566
UNKNOWN
PHASE3
Statins for the Treatment of NASH
NCT04679376
ACTIVE_NOT_RECRUITING
PHASE2
A Phase 3 STudy of CaPRe in LOwering Very hiGh TriglYcerides (TRILOGY 2)
NCT03361501
COMPLETED
PHASE3
Efficacy and Safety of JTT-705 300, 600 And 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia
NCT00686010
COMPLETED
PHASE2
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
NCT02944383
COMPLETED
PHASE2
A Phase 3 Study to Evaluate the Efficacy and Safety of K-877 in Chinese Patients With High TG and Low HDL-C
NCT04998981
COMPLETED
PHASE3
Monthly And Twice Monthly Subcutaneous Dosing Of PF-04950615 (RN316) In Hypercholesterolemic Subjects On A Statin
NCT01592240
COMPLETED
PHASE2
Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL
NCT01047683
COMPLETED
PHASE3
Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lovaza® and Simvastatin Therapy in Hypertriglyceridemic Subjects
NCT00903409
COMPLETED
PHASE3
GW501516 In Subjects Who Have Low Level Of High-Density Lipoprotein Cholesterol
NCT00158899
COMPLETED
PHASE2
A Study To Assess The Safety Of PF-05335810 In Hypercholesterolemic Subjects
NCT01720537
COMPLETED
PHASE1
A Confirmatory Trial of ETC-1002 in Patients With Hyper-LDL Cholesterolemia
NCT05683340
COMPLETED
PHASE3
A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides
NCT01262638
COMPLETED
PHASE2
A Study Comparing The Efficacy & Safety Of Torcetrapib/Atorvastatin And Atorvastatin In Subjects With High Triglycerides
NCT00134498
COMPLETED
PHASE3
Effect of Gemfibrozil on Serum Glycosylphosphatidylinositol (GPI) Phospholipase D and Triglycerides
NCT00108511
COMPLETED
PHASE1
Evaluation of ETC-1002 vs Placebo in Patients Receiving Ongoing Statin Therapy
NCT02072161
COMPLETED
PHASE2
A Phase 3 STudy of CaPRe In LOwering Very hiGh TriglYcerides (TRILOGY 1)
NCT03398005
COMPLETED
PHASE3
A Study of the Efficacy and Safety of ETC-1002 in Participants With Statin Intolerance
NCT01751984
COMPLETED
PHASE2
Efficacy and Safety Study of JTT-705 in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia
NCT00688896
COMPLETED
PHASE2
Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant
NCT02988115
COMPLETED
PHASE3
Safety and Efficacy Study of JTT-705 in Combination With Simvastatin 40 mg in Patients With Low High-Density Lipoprotein (HDL) Levels
NCT00688558
COMPLETED
PHASE2
A Pilot Study to Assess the Efficacy and Safety of LCQ908 Alone and in Combination With Fenofibrate or Lovaza® in Patients With Severe Hypertriglyceridemia
NCT01594983
COMPLETED
PHASE2
Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins
NCT02135029
COMPLETED
PHASE3
A Multiple Dose Study of PF-04950615 (RN316) in Subjects on High Doses of Statins
NCT01342211
COMPLETED
PHASE2
A Study of Evacetrapib in Healthy Participants
NCT01736254
COMPLETED
PHASE1